Published in J Neurol on October 24, 2016
Role of APP Interactions with Heterotrimeric G Proteins: Physiological Functions and Pathological Consequences. Front Mol Neurosci (2017) 0.75
Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome. Neuroimage Clin (2017) 0.75
A microRNA cluster (let-7c, miRNA-99a, miRNA-125b, miRNA-155 and miRNA-802) encoded at chr21q21.1-chr21q21.3 and the phenotypic diversity of Down's syndrome (DS; trisomy 21). J Nat Sci (2017) 0.75
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 19.19
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA (2003) 6.34
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol (1985) 3.83
The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem (2009) 3.45
Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol (1994) 3.19
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature (2016) 3.06
Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature (2010) 2.80
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry (2012) 2.68
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Biomarker modeling of Alzheimer's disease. Neuron (2013) 2.51
Statins for the prevention of dementia. Cochrane Database Syst Rev (2009) 2.38
Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev Med Child Neurol (2004) 2.33
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol (2012) 2.22
Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet (2003) 1.91
Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome. Br J Psychiatry (1998) 1.86
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett (2007) 1.80
Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci (2007) 1.65
A prospective study of Alzheimer disease in Down syndrome. Arch Neurol (1989) 1.64
Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol (2006) 1.63
Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry (2008) 1.54
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement (2012) 1.53
Dementia and mortality in persons with Down's syndrome. J Intellect Disabil Res (2006) 1.48
Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry (2002) 1.42
Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin Neurol Neurosurg (2011) 1.42
Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis (2012) 1.39
Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37
Developing β-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem (2011) 1.37
Down's syndrome and Alzheimer's disease: a review. Psychol Med (1986) 1.31
Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis (2012) 1.31
'Clinical trials in Alzheimer's disease': immunotherapy approaches. J Neurochem (2011) 1.29
Down syndrome, Alzheimer's disease and seizures. Brain Dev (2005) 1.29
BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. FASEB J (2006) 1.28
Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging (2005) 1.24
Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. PLoS One (2010) 1.23
The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol (2005) 1.23
Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett (2001) 1.21
Dementia in people with Down's syndrome. Int J Geriatr Psychiatry (2001) 1.20
Meta-analysis of modifiable risk factors for Alzheimer's disease. J Neurol Neurosurg Psychiatry (2015) 1.20
Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun (2014) 1.16
Diagnosing Alzheimer's dementia in Down syndrome: problems and possible solutions. Res Dev Disabil (2009) 1.15
Electroencephalography and event-related potentials as biomarkers of mild cognitive impairment and mild Alzheimer's disease. Alzheimers Dement (2007) 1.12
Microglia activation in the brain as inflammatory biomarker of Alzheimer's disease neuropathology and clinical dementia. Dis Markers (2006) 1.12
Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing. J Nutr Health Aging (2009) 1.07
CSF biomarkers: pinpointing Alzheimer pathogenesis. Ann N Y Acad Sci (2009) 1.06
Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. Behav Genet (2006) 1.04
Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport (2001) 1.04
Personality and behaviour changes mark the early stages of Alzheimer's disease in adults with Down's syndrome: findings from a prospective population-based study. Int J Geriatr Psychiatry (2006) 1.04
Executive dysfunction and its association with personality and behaviour changes in the development of Alzheimer's disease in adults with Down syndrome and mild to moderate learning disabilities. Br J Clin Psychol (2008) 1.02
Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. Arch Neurol (1995) 1.02
Adipokines: a link between obesity and dementia? Lancet Neurol (2014) 0.99
Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am J Ment Retard (1997) 0.98
Advances in the development of vaccines for Alzheimer's disease. Discov Med (2013) 0.97
Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS One (2010) 0.97
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci (2015) 0.96
Change in plasma Aß peptides and onset of dementia in adults with Down syndrome. Neurology (2010) 0.96
Neuropathologic changes in Alzheimer's disease: potential targets for treatment. J Clin Psychiatry (2006) 0.95
Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome. Neurobiol Aging (2011) 0.94
Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome. Brain (2014) 0.94
The modified CAMDEX informant interview is a valid and reliable tool for use in the diagnosis of dementia in adults with Down's syndrome. J Intellect Disabil Res (2004) 0.94
Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events. Neuroimage (2007) 0.93
APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. Neurology (1999) 0.93
Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener Dis (2010) 0.93
The amyloid cascade hypothesis. Alzheimers Dement (2008) 0.93
Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome. Neurosci Lett (2010) 0.92
Potential new diagnostic tool for Alzheimer's disease using a linear discriminant function for Fourier domain optical coherence tomography. Invest Ophthalmol Vis Sci (2014) 0.92
Brain anatomy and ageing in non-demented adults with Down's syndrome: an in vivo MRI study. Psychol Med (2009) 0.91
Some morphometric observations on the brains of patients with Down's syndrome: their relationship to age and dementia. J Neurol Sci (1990) 0.90
Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome. FASEB J (2006) 0.90
Gamma secretase-activating protein is a substrate for caspase-3: implications for Alzheimer's disease. Biol Psychiatry (2014) 0.90
A critical analysis of the 'amyloid cascade hypothesis'. Folia Neuropathol (2014) 0.90
Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease. Curr Gerontol Geriatr Res (2012) 0.90
Detection of Retinal Nerve Fiber Layer Defects in Alzheimer's Disease Using SD-OCT. Front Psychiatry (2014) 0.89
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study. Int J Geriatr Psychiatry (2002) 0.88
Alzheimer's disease and Down's syndrome: an in vivo MRI study. Psychol Med (2008) 0.88
Alzheimer's disease. A firm base for drug development. Nature (1999) 0.87
The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement (2015) 0.85
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides (2015) 0.85
Dementia in Down's syndrome. Lancet Neurol (2016) 0.85
Evidence-based evaluation of diagnostic accuracy of resting EEG in dementia and mild cognitive impairment. Clin EEG Neurosci (2009) 0.85
The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Front Behav Neurosci (2015) 0.84
Age-related cognitive decline and electroencephalogram slowing in Down's syndrome as a model of Alzheimer's disease. Neuroscience (1993) 0.84
Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down's syndrome from dementia. Neuroreport (1994) 0.82
Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia. Alzheimers Dement (2015) 0.81
Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's disease. Bioorg Med Chem Lett (2015) 0.81
Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapy. Electrophoresis (2012) 0.81
Anilinotriazoles as potent gamma secretase modulators. Bioorg Med Chem Lett (2014) 0.81
Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid. Neurodegener Dis (2014) 0.80
Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down's syndrome. Eur Neurol (1998) 0.78
Quinones bearing non-steroidal anti-inflammatory fragments as multitarget ligands for Alzheimer's disease. Bioorg Med Chem Lett (2013) 0.78